Pharmaceutical quality and corrective action management system

The quality team investigates deviations, locates related batches and assigns repair and prevention work. Before the investigation is completed, it is checked that the actions have yielded the intended result.

The production, laboratory and deviation evaluation states are not always linked to the release basis required for a particular batch or product. The reviewer has to check by hand whether all relevant decisions have been received and if any outstanding restrictions remain.

How the solution works

  1. Deviation is recorded with product, operation and primary evidence.
  2. The investigator collects the relevant sources and determines the reasonable extent of the affected batches or units.
  3. The cause hypotheses are evaluated and the action required is confirmed.
  4. Designated personnel perform corrective and preventive actions (CAPA) and provide evidence of their performance.
  5. The quality team verifies the effectiveness and forwards the relevant decision to the product review.

Key challenges

  • Quality control is disconnected from production
  • Limited batch and component traceability
  • Deviation studies are based on manual data collection

Solution capabilities

Deviation recording

The fact, its circumstances and the source reference are linked to the specific scope of the investigation.

Search for Impact and Traceability

Relationships between materials, equipment and process help identify affected stocks, products and deliveries.

Reason assessment

The hypothesis is separated from the proven conclusion, preserving the assessor's arguments.

CAPA Enforcement

The action has an owner, a deadline, a result and a default performance check.

Transfer of Quality Decisions

The professional responsible for releasing the batch or product sees the restrictions and approvals in place regarding their cancellation.

Business context

Quality control is disconnected from production
The production, laboratory and deviation evaluation states are not always linked to the release basis required for a particular batch or product. The reviewer has to check by hand whether all relevant decisions have been received and if any outstanding restrictions remain.
Limited batch and component traceability
Records of the material, component and operations performed are not always linked to the final batch or serial unit. Once a discrepancy is identified, the links have to be restored from multiple sources. It takes time to identify the affected stocks, deliveries and recipients. The quality team cannot quickly provide specific information to the developer or justify the scope of further action.
Deviation studies are based on manual data collection
The researcher collects data on the process, facilities, laboratories, materials and previous events by hand. Research takes a long time, causes are determined unevenly and batch release is delayed.
The Quality Question Has a Reasonable Answer
It is important for the customer to understand which production has been affected by the deviation and how the probability of its recurrence is reduced. Linking the data of the survey, actions and their effectiveness allows for a consistent response. This helps to address claims and continue cooperation based on documented decisions.

Core features

  • Deviation recording
  • Search for Impact and Traceability
  • Reason assessment
  • CAPA Enforcement
  • Transfer of Quality Decisions

Key integrations

Source of production and electronic record
Actual operations, materials, versions and endorsements.
Laboratory Information Management System (LIMS)
Test results with sample, method and review relationship.
Equipment Maintenance Process
Repair, state of use and period relevant to the event in question.
Warehouse and dispatch sources
Movement of lots, recipients and confirmed stockholding or other restriction.

Potential impact (%)

The ranges indicate an illustrative relative change in the metric under the stated assumptions. Results depend on the starting position and actual use of the solution. Percentages for different metrics must not be added together.

Time of collection of investigative documents

16–42%Decreasing

This illustrative scenario assumes that 40-70% of information searches and repeated cross-checks can be addressed. That share is assumed to fall by 40-60%. Company data is needed to verify both the addressable workload and the resulting change.

Active assembly and correction of missing links for research of similar scope are measured.

Repeated deviations after an approved action

2–12%Decreasing

This illustrative scenario assumes that the controls described can address 10-30% of discrepancies. That share is assumed to fall by 20-40%. Company data is needed to verify both the addressable share and the resulting change.

Repetition during the intended observation period is evaluated, taking into account changes in process and product.

Conditional calculation scenarios. The assumptions have not been validated against client measurements.

When this solution is relevant

  • Evidence of tests and deviations has been collected, but it is difficult to determine which batch or volume of units they are affected by.
  • The corrective action is closed after the task has been completed without an agreed performance assessment.

Implementation requirements

The quality team agrees on where they find the records needed for the study, how the related batches are determined and how they check the result of the correction. Additional search or integration functions are combined with the quality system that is already in use.

Further development options

  • Comparison of previous CAPA efficacy in a new study
  • Linking recipients' endorsements at the time of attempted cancellation

Frequently asked questions

Adapting the solution to your business